ND: |
ME14677191 |
PMID: |
14677191 |
LR: |
20061115 |
CED: |
20031216 |
DCO: |
20040105 |
Autoren: |
El Hajjaji H; Marcelis A; Devogelaer JP; Manicourt DH |
Titel: |
Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. |
Quelle: |
The Journal of rheumatology; VOL: 30 (11); p. 2444-51 /200311/ |
PM: |
Print |
SU: |
IM |
Sprache: |
English |
CY: |
Canada |
JID: |
7501984 |
ISSN: |
0315-162X |
CO: |
JRHUA9 |
Institution: |
ICP Christian de Duve Institute of Cellular Pathology and the Department of Rheumatology, Saint-Luc University Hospital, Catholic University of Louvain, Avenue Mounier, 1200 Brussels, Belgium. |
DT: |
In Vitro; Journal Article; Research Support, Non-U.S. Gov't |
Schlagwörter |
CT: |
AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/administration & dosage; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/*pharmacology; CARTILAGE, ARTICULAR/*drug effects; CARTILAGE, ARTICULAR/metabolism; DICLOFENAC/pharmacology; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYALURONIC ACID/biosynthesis; HYALURONIC ACID/*metabolism; MALE; MIDDLE AGED; OSTEOARTHRITIS/*metabolism; PROTEOGLYCANS/biosynthesis; PROTEOGLYCANS/*metabolism; PYRAZOLES; SULFONAMIDES/administration & dosage; SULFONAMIDES/*pharmacology |
CTG: |
ALTE MENSCHEN; ANTIPHLOGISTIKA, NICHTSTEROIDALE/Verabreichung & Dosierung; ANTIPHLOGISTIKA, NICHTSTEROIDALE/*Pharmakologie; KNORPEL, GELENK-/*Arzneimittelwirkungen; KNORPEL, GELENK-/Stoffwechsel; DICLOFENAC/Pharmakologie; DOSIS-WIRKUNGSBEZIEHUNG, ARZNEIMITTEL-; WEIBLICH; MENSCH; HYALURONSÄURE/Biosynthese; HYALURONSÄURE/*Stoffwechsel; MÄNNLICH; MENSCHEN IM MITTLEREN LEBENSALTER; OSTEOARTHROSE/*Stoffwechsel; PROTEOGLYCANE/Biosynthese; PROTEOGLYCANE/*Stoffwechsel; PYRAZOLE; SULFONAMIDE/Verabreichung & Dosierung; SULFONAMIDE/*Pharmakologie |
TE: |
Anti-Inflammatory Agents, Non-Steroidal; Proteoglycans; Pyrazoles; Sulfonamides; Diclofenac/15307-86-5; celecoxib/169590-42-5; Hyaluronic Acid/9004-61-9 |
CR: |
15307-86-5; 169590-42-5; 9004-61-9 |
AB: |
OBJECTIVE: To assess the effects of celecoxib, a cyclooxygenase (COX-2) selective inhibitor, on the metabolism of hyaluronan (HA) and proteoglycans (PG) in human cartilage explants with midrange severity of osteoarthritis (OA). Results were compared with those of diclofenac, a non-selective COX inhibitor. METHODS: Cartilage specimens (OA grade 4-8 on Mankin's scale) were pulsed with 3H -glucosamine and chased in the absence or presence of 1-10 micro g/ml of celecoxib or diclofenac. After papain digestion, the labeled chondroitin sulfate and HA molecules were purified by anion-exchange chromatography. RESULTS: Diclofenac did not affect the metabolic balance of PG and HA whereas, in a relatively dose-dependent manner, celecoxib increased the synthesis of HA and PG; celecoxib also reduced the net loss of labeled HA and PG molecules from cartilage explants. CONCLUSION: In short term in vitro cultures, celecoxib has a favorable effect on the overall metabolism of PG and HA. It is therefore unlikely that this drug would have a detrimental effect on articular cartilage during longterm administration. Further, celecoxib might help counteract the depletion of HA seen in OA cartilage. |